

1P-461-C100

Monoclonal Antibody to CD262 / TRAIL-R2 Phycoerythrin (PE) conjugated (0.1 mg)

Clone: DR5-01-1 Isotype: Mouse IqG1

Specificity: The antibody DR5-01-1 recognizes an extracellular domain of TRAIL-R2 (DR5).

TRAIL-R2 is one of two TNF superfamily member intracellular death domain

containing receptors for TRAIL (APO2L).

Regulatory Status: RUO

Immunogen: Recombinant fusion protein of human IgG heavy chain and extracellular domain of

DR5.

Species Reactivity: Human

Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum

conditions. The conjugate is purified by size-exclusion chromatography.

Concentration: 0.1 mg/ml

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis.

Suggested working dilution is 5 µg/ml. Indicated dilution is recommended starting

point for use of this product. Working concentrations should be determined by the

investigator.

Expiration: See vial label

Lot Number: See vial label

Background: TRAIL-R2 (CD262, DR5) is one of two TNF superfamily member intracellular death

domain containing receptors for TRAIL (APO2L). Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

For laboratory research only, not for drug, diagnostic or other use.



PRODUCT DATA SHEET

References:

*Corallini F, Milani D, Nicolin V, Secchiero P: TRAIL, caspases and maturation of normal and leukemic myeloid precursors. Leuk Lymphoma. 2006 Aug;47(8):1459-68.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.